HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: An in silico approach

Vaccine

Volumn 31, Issue 18, 2013, Pages 2289-2294

  Yao, Yufeng ^a   Huang, Weiwei ^a   Yang, Xu ^a   Sun, Wenjia ^a   Liu, Xin ^a   Cun, Wei ^a   Ma, Yanbing ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

Cervical cancer; Cytotoxic T lymphocytes (CTL); Human leukocyte antigen (HLA); Human papillomavirus (HPV); In silico approach; T cell epitopes

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; PROTEIN E6; PROTEIN E7;

ARTICLE; CLUSTER ANALYSIS; COMPUTER PREDICTION; CYTOTOXIC T LYMPHOCYTE; GENE CLUSTER; GENE FREQUENCY; GENE LOCUS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION CONTROL; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

AMINO ACID SEQUENCE; CLUSTER ANALYSIS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE FREQUENCY; HLA-A ANTIGENS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 84875865996     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.065     Document Type: Article

References (44)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(September (1)):12-19.
2. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(June (11)):796-802.
3. Hung C.F., Ma B., Monie A., Tsen S.W., Wu T.C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008, 8(April (4)):421-439.
4. Crow J.M. HPV: the global burden. Nature 2012, 488(August (7413)):S2-S3.
5. Sigurdsson K., Taddeo F.J., Benediktsdottir K.R., Olafsdottir K., Sigvaldason H., Oddsson K., et al. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer 2007, 121(December (12)):2682-2687.
6. Longworth M.S., Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004, 68(June (2)):362-372.
7. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 2002, 89(November (2)):213-228.
8. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996, 56(October (20)):4620-4624.
9. Crook T., Tidy J.A., Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991, 67(November (3)):547-556.
10. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(May (5)):342-350.
11. von Knebel Doeberitz M., Bauknecht T., Bartsch D., zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci U S A 1991, 88(February (4)):1411-1415.
12. von Knebel Doeberitz M., Oltersdorf T., Schwarz E., Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988, 48(July (13)):3780-3786.
13. Liu D.W., Yang Y.C., Lin H.F., Lin M.F., Cheng Y.W., Chu C.C., et al. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. J Virol 2007, 81(March (6)):2869-2879.
14. Frazer I.H., Quinn M., Nicklin J.L., Tan J., Perrin L.C., Ng P., et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004, 23(November (2)):172-181.
15. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008, 14(January (1)):169-177.
16. van der Burg S.H., de Jong A., Welters M.J., Offringa R., Melief C.J. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002, 89(November (2)):275-284.
17. Schwartz R.H. T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 1985, 3:237-261.
18. Bauer M., Wagner H., Lipford G.B. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Immunol Lett 2000, 71(January (1)):55-59.
19. Chen W., Yan W., Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 2008, 57(April (4)):517-530.
20. Evans E.M., Man S., Evans A.S., Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997, 57(July (14)):2943-2950.
21. Fonteneau J.F., Larsson M., Somersan S., Sanders C., Munz C., Kwok W.W., et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001, 258(December (1-2)):111-126.
22. Jochmus I., Osen W., Altmann A., Buck G., Hofmann B., Schneider A., et al. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J Gen Virol 1997, 78(July (Pt 7)):1689-1695.
23. Kaufmann A.M., Nieland J., Schinz M., Nonn M., Gabelsberger J., Meissner H., et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001, 92(April (2)):285-293.
24. Morishima S., Akatsuka Y., Nawa A., Kondo E., Kiyono T., Torikai H., et al. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope. Int J Cancer 2007, 120(February (3)):594-604.
25. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6(September (9)):3406-3416.
26. Ressing M.E., Sette A., Brandt R.M., Ruppert J., Wentworth P.A., Hartman M., et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995, 154(June (11)):5934-5943.
27. Ressing M.E., van Driel W.J., Celis E., Sette A., Brandt M.P., Hartman M., et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996, 56(February (3)):582-588.
28. Schreurs M.W., Scholten K.B., Kueter E.W., Ruizendaal J.J., Meijer C.J., Hooijberg E. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 2003, 171(September (6)):2912-2921.
29. Steller M.A., Gurski K.J., Murakami M., Daniel R.W., Shah K.V., Celis E., et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998, 4(September (9)):2103-2109.
30. Kast W.M., Brandt R.M., Sidney J., Drijfhout J.W., Kubo R.T., Grey H.M., et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994, 152(April (8)):3904-3912.
31. Nilges K., Hohn H., Pilch H., Neukirch C., Freitag K., Talbot P.J., et al. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 2003, 77(May (9)):5464-5474.
32. Youde S.J., Dunbar P.R., Evans E.M., Fiander A.N., Borysiewicz L.K., Cerundolo V., et al. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 2000, 60(January (2)):365-371.
33. Youde S.J., McCarthy C.M., Thomas K.J., Smith K.L., Man S. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 2005, 114(April (4)):606-612.
34. Solberg O.D., Mack S.J., Lancaster A.K., Single R.M., Tsai Y., Sanchez-Mazas A., et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol 2008, 69(July (7)):443-464.
35. Cohen T., Moise L., Martin W., Groot A.S.D. Immunoinformatics: the next step in vaccine design. Infect Dis Inform 2010, 223-244.
36. Tong J.C., Ren E.C. Immunoinformatics: current trends and future directions. Drug Discov Today 2009, 14(July (13-14)):684-689.
37. Bourgault Villada I., Moyal Barracco M., Berville S., Bafounta M.L., Longvert C., Premel V., et al. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol 2010, 159(January (1)):45-56.
38. Mizuuchi M., Hirohashi Y., Torigoe T., Kuroda T., Yasuda K., Shimizu Y., et al. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses. Exp Mol Pathol 2012, 92(February (1)):185-190.
39. Zehbe I., Voglino G., Delius H., Wilander E., Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998, 352(October (9138)):1441-1442.
40. Wu Y., Chen Y., Li L., Yu G., He Y., Zhang Y. Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China. The Journal of general virology 2006, 87(May (Pt 5)):1181-1188.
41. Gostout B.S., Zanetta G.M., Maleemonkol S., Kamat M.R., McGovern R.M., Persing D.H. Differential distribution of sequence variations in HPV-16 E6. Gynecol Oncol 2000, 79(October (1)):11-17.
42. Riemer A.B., Keskin D.B., Zhang G., Handley M., Anderson K.S., Brusic V., et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem 2010, 285(September (38)):29608-29622.
43. Jang S., Kim Y.T., Chung H.W., Lee K.R., Lim J.B., Lee K. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer. Cancer 2012, 118(April (8)):2173-2183.
44. Davidson E.J., Boswell C.M., Sehr P., Pawlita M., Tomlinson A.E., McVey R.J., et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003, 63(September (18)):6032-6041.